Abstract:Background: Observational studies suggest an association between blood pressure (BP) and functional outcomes in ischemic stroke patients but whether this is causal or due to confounding is uncertain. We used Mendelian randomization (MR) to assess causality, and also explore whether particular classes of anti-hypertensives were associated with a better outcome after ischemic stroke. Methods: We selected genetic variants associated with systolic and diastolic BP and BP-lowering variants in genes encoding antihypertensive drugs from genome-wide association studies (GWAS) on 757,601 individuals. The primary outcome was 3-month dependence or death defined as a modified Rankin Scale (mRS) of 3-6. The secondary outcome was disability or death after 90 days defined as mRS 2-6. Cochran's Q statistic in the inverse variance weighted (IVW) model, the weighted median, MR-Egger regression, leave-one-single-nucleotide polymorphism (SNP)-out analysis, MR-Pleiotropy Residual Sum and Outlier methods were adopted as sensitivity analyses. To validate our primary results, we performed independent repeat analyses and Bi-directional MR analyses. Results: Genetic predisposition to higher systolic and diastolic BP was associated with disability or death after ischemic stroke in univariable IVW MR analysis (odds ratio (OR) 1.29, 95% confidence interval (CI): 1.05-1.59, p = 0.014; OR 1.27, 95% CI: 1.07-1.51, p = 0.006, respectively). Pulse pressure was associated with both dependence or death and disability or death after ischemic stroke (OR = 1.05, 95% CI: 1.02-1.08, p = 0.002; OR = 1.04, 95% CI = 1.01-1.07, p = 0.009, respectively). Angiotensin-converting enzyme inhibitor (ACEI) and calcium channel blocker (CCB) were significantly associated with improved functional outcomes (dependence or death, OR 0.76, 95% CI: 0.62-0.94, p = 0.009; OR 0.89, 95% CI: 0.83-0.97, p = 0.005). Proxies for & beta;-blockers, angiotensin receptor blockers (ARB), and thiazides failed to show associations with functional outcomes (p > 0.05). Conclusion: We provide evidence for an association of genetic predisposition to higher BP with a higher risk of 3-month functional dependence after ischemic stroke. Our findings support ACEI and CCB as promising antihypertensive drugs for improving functional outcomes in ischemic stroke.

Causal relationship between genetic proxies for calcium channel blockers and the risk of depression: a drug-target Mendelian randomization study

The causal relationship between antihypertensive drugs and depression: a Mendelian randomization study of drug targets

Causal effects between negative moods and cardiovascular diseases: a Mendelian randomization study

Genetic Liability to Depression and Risk of Coronary Artery Disease, Myocardial Infarction, and Other Cardiovascular Outcomes.

Association of Antihypertensive Drugs with COVID-19 Outcomes: a Drug-Target Mendelian Randomization Study

Heartache and Heartbreak: An Observational and Mendelian Randomization Study

Major depressive disorder increased the risk of hypertension: A Mendelian randomization study

A Mendelian randomization study of the effect of mental disorders on cardiovascular disease

Genetically Determined Blood Pressure, Antihypertensive Medications, and Risk of Intracranial Aneurysms and Aneurysmal Subarachnoid Hemorrhage: A Mendelian Randomization Study

Distinct Effects of Antihypertensives on Depression in the Real-World Setting: A Retrospective Cohort Study.

Genetic evidence suggests that depression increases the risk of erectile dysfunction: A Mendelian randomization study

Depression and Prostate Cancer Risk: A Mendelian Randomization Study

Association Between Blood Pressure and Different Antihypertensive Drugs with Outcome after Ischemic Stroke: A Mendelian Randomization Study.

Association of Cortisol Levels with Neuropsychiatric Functions: A Mendelian Randomization Analysis

Major depression and small vessel stroke: a Mendelian randomization analysis

Investigating the association of the effect of genetically proxied PCSK9i with mood disorders using cis-pQTLs: A drug-target Mendelian randomization study

Genetically Determined Blood Pressure, Antihypertensive Medications, and Risk of Alzheimer’s Disease: A Mendelian Randomization Study

Investigating Genetic Causal Relationships Between Blood Pressure and Anxiety, Depressive Symptoms, Neuroticism and Subjective Well-Being

Risk Factors of Depression Screened by Two-Sample Mendelian Randomization Analysis: A Systematic Review

Investigating the causal relationship between major depressive disorder and benign prostatic hyperplasia: a bidirectional Mendelian randomisation study

Genetically predicted circulating levels of cytokines and the risk of depression: a bidirectional Mendelian-randomization study